Article

Phosphorylation of RasGRP3 on threonine 133 provides a mechanistic link between PKC and Ras signaling systems in B cells.

Department of Biochemistry, University of Alberta, Edmonton AB, Canada.
Blood (Impact Factor: 9.78). 06/2005; 105(9):3648-54. DOI: 10.1182/blood-2004-10-3916
Source: PubMed

ABSTRACT B-cell receptor (BCR) signaling activates a number of intracellular signaling molecules including phospholipase C-gamma2 (PLC-gamma2), which generates membrane diacylglycerol (DAG). DAG recruits both protein kinase C (PKC) and RasGRP family members to the membrane and contributes to their activation. We have hypothesized that membrane colocalization facilitates activation of RasGRP3 by PKC. Here we demonstrate that PKC phosphorylates RasGRP3 on Thr133 in vitro, as determined by mass spectrometry. RasGRP3 with a Thr133Ala substitution is a poor PKC substrate in vitro and a poor Ras activator in vivo. Antiphosphopeptide antibodies recognize Thr133-phosphorylated RasGRP3 in B cells after BCR stimulation or DAG analog treatment, but much less so in resting cells. PKC inhibitors block RasGRP3 Thr133 phosphorylation and Ras-extracellular signal-related kinase (Erk) signaling with a similar pattern. After stimulation of T-cell receptor (TCR) or DAG analog treatment of T cells, PKC-catalyzed phosphorylation of RasGRP1 occurs on the homologous residue, Thr184. These studies shed light on the proposed "PKC-Ras pathway" and support the hypothesis that RasGRP phosphorylation by PKC is a mechanism that integrates DAG signaling systems in T and B cells. PKC-mediated regulation of RasGRPs in lymphocytes may generate cooperative signaling in response to increases in DAG. The mast- and myeloid-selective family member RasGRP4 is regulated by different means.

0 Followers
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Diffuse large B cell lymphomas can be cured in about 60% of cases with immuno-chemotherapy. However, a large subset of patients with DLBCL does not go into remission or relapse after first line therapy. Further therapy options are therefore needed. PLCgamma2 is one of the key regulators of the B cell receptor signaling pathway, which targets several pro-proliferative factors, such as NFkB, Ras and Akt. Using immunohistochemistry, we found that PLCgamma2 was strongly expressed in 63% of DLBCL cases. The PLC-inhibitor U73122 had inhibitory effect on cell proliferation, induced apoptosis and G0/G1 cell cycle arrest. Co-treatment with Enzastaurin or the Src-inhibitor pp2 together with U73122 had an additive effect on cell proliferation compared to U73122 alone. Unexpectedly, strong PLCgamma2 expression was associated with better overall survival. In conclusion, PLCgamma2 is strongly expressed in a significant number of DLBCL and has prognostic implications. Inhibition of PLCgamma2 could be a new target for lymphoma treatment.
    Leukemia and Lymphoma 07/2014; DOI:10.3109/10428194.2014.941832 · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stimulation of the µ‑opioid receptor activates extracellular signal‑regulated kinase (ERK), however, the mechanism by which this occurs remains to be elucidated. Phosphatidylethanolamine‑binding protein (PEBP) has been reported to act as a negative regulator of the ERK cascade (Raf‑MEK‑ERK) by binding to Raf‑1 kinase. In the present study, the role of PEBP in µ‑opioid receptor‑mediated ERK activation was investigated in Chinese hamster ovary/µ cells and SH‑SY5Y cells, as well as in human embryonic kidney 293 cells expressing other types of G protein‑coupled receptors. The acute activation of µ‑opioid receptors by morphine or (D‑Ala2, MePhe4, Gly5‑ol) enkephalin induced a rapid activation of ERK. Prolonged morphine treatment did not affect the phosphorylation level of ERK compared with control cells, but the phosphorylation level of ERK decreased markedly when cells were precipitated with naloxone following chronic morphine treatment. For the phosphorylation of PEBP, no change was identified under the designated drug treatment and exposure duration. A total of two other types of G protein‑coupled receptors, including Gs‑coupled dopamine D1 receptors and Gq‑coupled adrenergic α1A receptors were also investigated and only the activation of adrenergic α1A receptors induced an upregulated phosphorylation of PEBP, which was protein kinase C activity dependent. Thus, PEBP did not have a significant role in µ‑opioid receptor‑mediated regulation of ERK.
    Molecular Medicine Reports 01/2015; DOI:10.3892/mmr.2015.3161 · 1.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Host immune cells can detect and destruct invading pathogens via pattern-recognition receptors. Small Rap GTPases act as conserved molecular switches coupling extracellular signals to various cellular responses, but their roles as regulators in Toll-like receptor (TLR) signalling have not been fully elucidated. Here we report that Ras guanine nucleotide-releasing protein 3 (RasGRP3), a guanine nucleotide-exchange factor activating Ras and Rap1, limits production of proinflammatory cytokines (especially IL-6) in macrophages by activating Rap1 on activation by low levels of TLR agonists. We demonstrate that RasGRP3, a dominant member of RasGRPs in macrophages, impairs TLR3/4/9-induced IL-6 production and relieves dextrane sulphate sodium-induced colitis and collagen-induced arthritis. In RasGRP3-deficient RAW264.7 cells obtained by CRISPR-Cas9 genome editing, TLR3/4/9-induced activation of Rap1 was inhibited while ERK1/2 activation was enhanced. Our study suggests that RasGRP3 limits inflammatory response by activating Rap1 on low-intensity pathogen infection, setting a threshold for preventing excessive inflammatory response.
    Nature Communications 08/2014; 5:4657. DOI:10.1038/ncomms5657 · 10.74 Impact Factor

Preview